Sun Pharmaceuticals
Sun Pharma Gets DCGI Nod for Generic Wegovy, Set for March Launch as Semaglutide Patent Nears Expiry
By Axel Miller | 23 Jan 2026
Sun Pharma has received DCGI approval for generic semaglutide for weight management and will launch Noveltreat after the semaglutide patent expires in March 2026.
Sun Pharma Advanced Research to Cut Workforce by 40% in Cost Optimisation Push
By Axel Miller | 08 Jan 2026
SPARC slashes 40% of workforce and consolidates labs to save $10M annually. Discover how the Sezaby PRV ruling could clear the firm’s $46M debt.
Sun Pharma to acquire oncology therapy company Checkpoint in US
11 Mar 2025
Sun Pharmaceutical Industries Ltd has entered into an agreement to acquire US-based immunotherapy and targeted oncology company, Checkpoint Therapeutics Inc
Taro to merge with Sun Pharma in $350 million deal
21 Jan 2024
Sun Pharmaceutical Industries Limited and Israel-based Taro Pharmaceutical Industries Ltd have entered into a definitive merger agreement under which Sun Pharma
Sun Pharma chairman Israel Makov to retire on 29 August
08 Aug 2022
Makov has played a significant role in Sun Pharma’s transformation from a $1.7 billion organisation focusing on India and the US into the world's fourth largest specialty generic pharmaceutical company operating across 100+ markets with a turnover of over $5 billion
Sun Pharma swings to Q2 net profit of Rs1,062 cr
07 Nov 2019
Sun Pharma Halol unit gets 3 adverse notices from US FDA: shares rise
24 Feb 2018
Although the strictures will impact Sun Pharmaceutical’s US business, the bourses took a positive view with the company’s shares actually rising, as the number of observations has come from the earlier nine to just three
